Bifogade filer
Sprint Bioscience recruits Niklas Axelsson as new CFO
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Sprint Bioscience today announced that Niklas Axelsson has been appointed as CFO. With over 25 years of experience in both the pharmaceutical industry and the finance sector, Niklas Axelsson will also join the company’s management team.
Niklas Axelsson brings extensive experience from nearly 20 years at AstraZeneca, where he held senior financial positions both in Sweden and internationally. Most recently, he served as CFO at the life science company ETAC. Prior to AstraZeneca, he worked in corporate finance at Danske Bank.
"With his unique expertise from both the pharmaceutical and finance sectors, Niklas Axelsson will play a crucial role in strengthening the company and supporting our continued growth. I am very pleased to welcome Niklas to our team," said Johan Emilsson, CEO of Sprint Bioscience.
"I look forward to joining Sprint Bioscience. With its strong pipeline and innovative research portfolio, I see great opportunities to contribute to the company’s success and create value for both shareholders and other stakeholders," said Niklas Axelsson, incoming CFO of Sprint Bioscience.
Niklas Axelsson will start his position as CFO at Sprint Bioscience on October 16 and immediately join the company’s management team. He will replace Mathias Skalmstad, who, after a handover period, will leave the company for a new role in another organization, as previously announced.